Jazz Pharmaceuticals plc Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2011 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Jazz Pharmaceuticals plc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2011 to Q2 2024.
  • Jazz Pharmaceuticals plc Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $56.7M, a 7.78% decline year-over-year.
  • Jazz Pharmaceuticals plc Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $227M, a 3.76% decline year-over-year.
  • Jazz Pharmaceuticals plc annual Share-based Payment Arrangement, Expense for 2023 was $227M, a 2.18% increase from 2022.
  • Jazz Pharmaceuticals plc annual Share-based Payment Arrangement, Expense for 2022 was $222M, a 17.5% increase from 2021.
  • Jazz Pharmaceuticals plc annual Share-based Payment Arrangement, Expense for 2021 was $189M, a 56.2% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $227M $56.7M -$4.78M -7.78% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $232M $61.4M +$5.09M +9.03% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $227M $52.9M -$8.62M -14% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $235M $56.1M -$566K -1% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 $236M $61.4M +$7.75M +14.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $228M $56.4M +$6.28M +12.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $222M $61.6M +$8.44M +15.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $214M $56.7M +$3.44M +6.47% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $210M $53.7M +$5.52M +11.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $205M $50.1M +$15.6M +45.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $189M $53.1M +$21.7M +69.3% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $167M $53.2M +$22.9M +75.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $144M $48.2M +$17.6M +57.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $127M $34.5M +$5.83M +20.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $121M $31.4M +$5.45M +21% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-01
Q3 2020 $116M $30.4M +$1.57M +5.46% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $114M $30.6M +$2.32M +8.18% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $112M $28.7M +$1.1M +4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 $111M $25.9M -$786K -2.94% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $111M $28.8M +$3.68M +14.7% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-02
Q2 2019 $108M $28.3M +$1.98M +7.51% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 $106M $27.6M +$3.25M +13.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q4 2018 $102M $26.7M -$598K -2.19% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-23
Q3 2018 $103M $25.1M -$2.02M -7.46% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $105M $26.3M -$948K -3.48% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $106M $24.3M -$890K -3.53% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 $107M $27.3M +$3.04M +12.5% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-25
Q3 2017 $104M $27.1M +$2.25M +9.05% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 $102M $27.3M +$1.83M +7.18% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $99.8M $25.2M +$1.01M +4.18% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q4 2016 $98.8M $24.3M -$36K -0.15% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-26
Q3 2016 $98.8M $24.9M +$1.76M +7.61% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 $97M $25.4M +$2.13M +9.16% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-08
Q1 2016 $94.9M $24.2M +$3.36M +16.2% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
Q4 2015 $91.6M $24.3M +$5.3M +27.9% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-27
Q3 2015 $86.3M $23.1M +$4.86M +26.6% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-08
Q2 2015 $81.4M $23.3M +$4.75M +25.6% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
Q1 2015 $76.6M $20.8M +$7M +50.7% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q4 2014 $69.6M $19M +$6.61M +53.2% Oct 1, 2014 Dec 31, 2014 10-K 2017-02-28
Q3 2014 $63M $18.3M +$6.38M +53.7% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-09
Q2 2014 $56.7M $18.6M +$7.05M +61.2% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-05
Q1 2014 $49.6M $13.8M +$5.06M +57.8% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-07
Q4 2013 $44.6M $12.4M +$4.3M +53% Oct 1, 2013 Dec 31, 2013 10-K 2016-02-23
Q3 2013 $40.3M $11.9M +$5.52M +86.9% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-04
Q2 2013 $34.7M $11.5M +$6.25M +119% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-05
Q1 2013 $28.5M $8.76M +$5.48M +167% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-08
Q4 2012 $23M $8.11M -$2.83M -25.9% Oct 1, 2012 Dec 31, 2012 10-K 2015-02-24
Q3 2012 $25.8M $6.36M +$3.16M +98.9% Jul 1, 2012 Sep 30, 2012 10-Q 2012-11-09
Q2 2012 $22.7M $5.26M +$1.84M +54% Apr 1, 2012 Jun 30, 2012 10-Q 2012-08-07
Q1 2012 $20.8M $3.28M +$133K +4.23% Jan 1, 2012 Mar 31, 2012 10-Q 2012-05-08
Q4 2011 $20.7M $10.9M Oct 1, 2011 Dec 31, 2011 10-K 2014-02-25
Q3 2011 $3.2M Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-09
Q2 2011 $3.42M Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-07
Q1 2011 $3.15M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.